women with osteoporosis: improving the measure-
ments of persistence on actonel treatment: the
impact study’. InEuropean Calcified Tissues Society
Meeting, Rome, 8–12 May.
Didlake RH, Dreyfus K, Kerman RH, Van Buren CT,
Kahan BD.1988. ‘Patient noncompliance: a major
cause of late graft failure in cyclosporine-treated
renal transplants’.Transplant Proc. 20 (Suppl. 3):
63–69.
Eastell R, Garnero P, Vrijens B, van de Langerijt L, Pols
HAP, Ringe JD,et al. 2003. ‘Influence of patient
compliance with risedronate therapy on bone turn-
over marker and bone mineral density response: the
impact study’. InEuropean Calcified Tissues Society
Meeting, Rome, 8–12 May.
Efron B. 1991. ‘Rejoinder’.J. Am. Stat. Assoc. 86 (413):
25.
Efron B. 1998. ‘Foreword – The Limburg Compliance
Symposium’.Stat. Med. 17 : 249–250.
Feely M, Cooke J, Price D, Singleton S, Mehta A,
Bradford L,et al. 1987. ‘Low-dose phenobarbitone
as an indicator of compliance with drug therapy’.Br.
J. Clin. Pharmacol. 24 : 77–83.
Feinstein AR. 1990. ‘On white-coat effects and the
electronic monitoring of compliance’.Arch. Intern.
Med. 150 : 1377–1378.
Heerdink ER, Urquhart J, Leufkens HG. 2002.
‘Changes in prescribed drug dose after market intro-
duction’.Pharmacoepidemiol Drug Safety 11 : 447–
453.
Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP.
- ‘Discontinuation of and changes in treatment
after start of new courses of antihypertensive drugs:
a study of a United Kingdom population’.Br. Med. J.
311 : 293–295.
Kass MA, Gordon M, Meltzer DW. 1986. ‘Can ophthal-
mologists correctly identify patients defaulting from
pilocarpine therapy?’.Am. J. Ophthalmol. 101 : 524–
Kastrissios H, Blaschke TF. 1997. ‘Medication com-
pliance as a feature in drug development.’Ann. Rev.
Pharmacol. Toxicol. 37 : 451–475.
Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum
B, Weber E. 1990. ‘Compliance with short-term
high-dose oestradiol in young patients with primary
infertility – new insights from the use of electronic
devices’.Agents Actions Suppl. 29 : 105–115.
Kruse W, Weber E. 1990. ‘Dynamics of drug regimen
compliance – its assessment by microprocessor-
based monitoring’.Eur. J. Clin. Pharmacol. 38 :
561–565.
Loeys T, Goetghebeur E. 2003. ‘Causal proportional
hazards estimator for the effect of treatment actually
received in a randomized trial with all-or-nothing
compliance’.Biometrics 59 : 100–105.
Meier P. 1991. ‘Discussion’. J. Am. Stat. Assoc.
86 (413): 19–22.
Me ́try JM, Meyer UA. 1999.Drug Regimen Compli-
ance: Issues in Clinical Trials and Patient Manage-
ment. John Wiley & Sons: New York.
Milgrom H, Bender B, Ackerson L, Bowry P, Smith B,
Rand C. 1996. ‘Non-compliance and treatment fail-
ure in children with asthma’.J. Allergy Clin. Immu-
nol. 98 : 1051–1057.
Nevins E, Kruse L, Skeans MA, Thomas W. ‘The
natural history of azathioprine compliance
after renal transplantation’.Kidney Int. 60 : 1565–
1570.
Norell SE. 1984. ‘Methods in assessing drug compli-
ance’.Acta Med. Scand. 683 (Suppl.): 35–40.
Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui
TS. ‘The relative risk of incident coronary heart
disease associated with recently stopping the use
of beta blockers’.JAMA 263 : 1653–1657.
Pocock SJ, Abdalla M. 1998. ‘The hope and the hazard
of using compliance data in randomized controlled
trials’.Stat. Med. 17 : 303–318.
Pullar T, Feely M. 1990. ‘Problems of compliance with
drug treatment: new solutions?’.Pharm. J. 245 :
213–215.
Pullar T, Kumar S, Chrystyn H, Rice P, Peaker S, Feely
M. 1991. ‘The prediction of steady-state plasma
phenobarbitone concentrations (following low-
dose phenobarbitone) to refine its use as an indicator
of compliance’.Br. J. Clin. Pharmacol. 32 : 329–
333.
Pullar T, Kumar S, Tindall H, Feely M. 1989. ‘Time to
stop counting the tablets?’.Clin. Pharmacol. Ther.
46 : 163–168.
Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D,
Schweizer R. 1989. ‘Noncompliance in organ trans-
plant recipients’.Transplant Proc. 21 : 833–834.
Rubin D. 1991. ‘Comment: dose-response estimands’.
J. Am. Stat. Assoc. 86 (413): 22–24.
Rubin DS. 1998. ‘More powerful randomization-based
p-values in double-blind trials with non compli-
ance’.Stat. Med. 17 : 371–386.
Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C,
Mitchell WD, Marshall G. 1989. ‘The natural his-
tory of medication compliance in a drug trial:
limitations of pill counts’.Clin. Pharmacol. Ther.
46 :169–176.372 CH27 PATIENT COMPLIANCE: PHARMIONICS, A NEW DISCIPLINE